Education
About Us
Working with TipRanks
Follow Us
Acarix AB (SE:ACARIX)
:ACARIX
ACARIX Stock Chart & Stats
kr0.28
>-kr0.01(-3.04%)
At close: 4:00 PM EST
kr0.28
>-kr0.01(-3.04%)
Day’s Range― - ―
52-Week Rangekr0.19 - kr0.47
Previous CloseN/A
Volume265.37K
Average Volume (3M)1.57M
Market Cap
kr337.00M
Enterprise Valuekr318.72M
Total Cash (Recent Filing)kr18.27M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,780,482
30 Day Avg. Volume1,572,056
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr26.90M
Bulls Say, Bears Say
Bulls Say
Installed-base Consumable ModelAcarix's CADScor business model monetizes both capital device sales and per-test consumables, creating a recurring revenue stream from each installed device. This structural revenue mix supports margin scalability as testing volumes grow and reduces sole reliance on new device sales for long-term revenue.
Positive Product-level Gross ProfitPositive gross profit shows the CADScor system yields healthy unit economics at the product level. If clinical adoption and utilization increase, these unit margins provide a foundation for improved operating leverage, enabling profitable scaling once fixed operating costs are controlled or reduced.
Very Low LeverageNear-zero debt limits fixed financial obligations and lowers bankruptcy risk, giving the company balance-sheet flexibility. This structural advantage eases the burden of interest costs, supports negotiations with partners or lenders, and preserves optionality for non-dilutive financing or strategic collaborations.
Bears Say
Very Large Operating LossesOperating losses are an order of magnitude larger than sales, showing the cost base far outstrips current revenue. This structural mismatch implies a lengthy path to breakeven, increases dependency on external funding, and constrains the firm's ability to reinvest in commercialization or R&D without dilution.
High Cash BurnSustained negative operating and free cash flow at this scale relative to revenue indicates limited self-funding capacity. The persistent burn requires ongoing financing, creates dilution or refinancing risk, and limits the company's ability to execute long-term commercial rollouts or secure larger payer contracts without external capital.
Eroding Equity And Shrinking AssetsSharp declines in shareholders' equity and total assets reflect repeated losses depleting the capital base. This structural erosion reduces the firm's financial cushion, limits capacity for investment or absorbing shocks, and can increase the cost and difficulty of raising future capital for durable growth.
Acarix AB News
ACARIX FAQ
What was Acarix AB’s price range in the past 12 months?
Acarix AB lowest stock price was kr0.19 and its highest was kr0.47 in the past 12 months.
What is Acarix AB’s market cap?
Acarix AB’s market cap is kr337.00M.
When is Acarix AB’s upcoming earnings report date?
Acarix AB’s upcoming earnings report date is May 20, 2026 which is in 63 days.
How were Acarix AB’s earnings last quarter?
Acarix AB released its earnings results on Feb 12, 2026. The company reported -kr0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.01.
Is Acarix AB overvalued?
According to Wall Street analysts Acarix AB’s price is currently Overvalued.
Does Acarix AB pay dividends?
Acarix AB does not currently pay dividends.
What is Acarix AB’s EPS estimate?
Acarix AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acarix AB have?
Acarix AB has 1,123,320,200 shares outstanding.
What happened to Acarix AB’s price movement after its last earnings report?
Acarix AB reported an EPS of -kr0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.649%.
Which hedge fund is a major shareholder of Acarix AB?
Currently, no hedge funds are holding shares in SE:ACARIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acarix AB
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.